Aegis Capital Upgrades Inovio Pharma (INO) to Buy Following VGX-3100 Phase 2 Update
Tweet Send to a Friend
Aegis Capital upgrades Inovio Pharma (AMEX: INO) from Hold to Buy and raises its target price from $10 to $19 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE